At eight months of follow-up, Jynneos recipients not vaccinated against smallpox had lower binding antibody concentrations than those with infection.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
In the US, officials are making more vaccine doses available.
Also, a review of clinical guidelines on monkeypox finds a dearth of good information.
New data suggest that vaccination of only known contacts may not by itself prevent transmission.
Also, 4 studies shed light on symptoms, diagnosis, and spread, with 1 paper detailing asymptomatic cases.
Maine, which has confirmed only four monkeypox cases, today reported a case of the virus in a resident under the age of 18. No further details were released by the Maine Centers for Disease Control. Maine now joins California and Florida as states with pediatric cases.
Also, researchers in Spain detail a possible human-to-dog case.
Despite concerns, US officials press ahead with intradermal injection strategy amid rising cases.
One day after the United States said it would allow intradermal, fractional dosing of Bavarian Nordic's monkeypox vaccine, Jynneos, the World Health Organization (WHO) called for more trials on the practice.
As part of the push, the CDC began sending clinicians educational materials on how to administer intradermal vaccines.
In other new developments, a preprint study found a low percentage of breakthrough infections in vaccinated people, and Israel reported an apparent infection from healthcare exposure.
Meanwhile, the CDC published a clinical and epidemiological snapshot of US cases, revealing that 42% didn't report prodrome symptoms.
